#MSVirtual2020 – New Safety, Efficacy Data on Mavenclad, Rebif and Evobrutinib on Way
EMD Serono will present new data from programs assessing the efficacy and safety of Mavenclad (cladribine) andĀ Rebif (interferon beta-1a), as well as investigative evobrutinibĀ in treatingĀ relapsing forms of multiple sclerosis (MS) at the MSVirtual2020 meeting. FindingsĀ are part of 54 abstracts being presented by EMD Serono,…